Cargando…

Incretin-Based Therapies: Viewpoints on the way to consensus

Detalles Bibliográficos
Autores principales:	Nauck, Michael. A., Vilsbøll, Tina, Gallwitz, Baptist, Garber, Alan, Madsbad, Sten
Formato:	Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2009
Materias:	Diabetes Progression, Prevention, and Treatment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2811437/ https://www.ncbi.nlm.nih.gov/pubmed/19875556 http://dx.doi.org/10.2337/dc09-S315

Ejemplares similares

Loss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 Diabetes
por: Holst, Jens J., et al.
Publicado: (2011)

Viewpoints on the Way to the Consensus Session: Where does insulin resistance start? The adipose tissue
por: Iozzo, Patricia
Publicado: (2009)

Viewpoints on the Way to a Consensus Session: Where does insulin resistance start? The liver
por: Perseghin, Gianluca
Publicado: (2009)

Incretin Effects on β-Cell Function, Replication, and Mass: The human perspective
por: Garber, Alan J.
Publicado: (2011)

Combined Pharmacologic/Nonpharmacologic Intervention in Individuals at High Risk of Developing Type 2 Diabetes: Pro pharmacologic therapy
por: Garber, Alan J.
Publicado: (2009)

Therapy in the Early Stage: Incretins
por: Cernea, Simona, et al.
Publicado: (2011)

Insulin Therapy for Type 2 Diabetes
por: Swinnen, Sanne G., et al.
Publicado: (2009)

How Do We Continue Treatment in Patients With Type 2 Diabetes When Therapeutic Goals Are Not Reached With Oral Antidiabetes Agents and Lifestyle? Incretin versus insulin treatment
por: Gallwitz, Baptist, et al.
Publicado: (2013)

Initiating Insulin Therapy in Type 2 Diabetic Patients Failing on Oral Hypoglycemic Agents: Basal or prandial insulin? The APOLLO trial and beyond
por: Bretzel, Reinhard G., et al.
Publicado: (2009)

Nonpharmacologic Therapy and Exercise in the Prevention of Type 2 Diabetes
por: Tuomilehto, Jaakko
Publicado: (2009)

β-Cell Protection and Therapy for Latent Autoimmune Diabetes in Adults
por: Cernea, Simona, et al.
Publicado: (2009)

The evolving place of incretin-based therapies in type 2 diabetes
por: Gallwitz, Baptist
Publicado: (2010)

Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A review of their efficacy and tolerability
por: Garber, Alan J.
Publicado: (2011)

Skeletal Muscle Insulin Resistance Is the Primary Defect in Type 2 Diabetes
por: DeFronzo, Ralph A., et al.
Publicado: (2009)

Goals of Treatment for Type 2 Diabetes: β-Cell preservation for glycemic control
por: Marchetti, Piero, et al.
Publicado: (2009)

Changing the Treatment Paradigm for Type 2 Diabetes
por: Del Prato, Stefano, et al.
Publicado: (2009)

Target for Glycemic Control: Concentrating on glucose
por: Monnier, Louis, et al.
Publicado: (2009)

Defining and Characterizing the Progression of Type 2 Diabetes
por: Fonseca, Vivian A.
Publicado: (2009)

Bile Acids and Metabolic Regulation: Mechanisms and clinical responses to bile acid sequestration
por: Staels, Bart, et al.
Publicado: (2009)

Early Insulin Treatment in Type 2 Diabetes: What are the pros?
por: Meneghini, Luigi F.
Publicado: (2009)

Where Does Insulin Resistance Start?: The brain
por: Pagotto, Uberto
Publicado: (2009)

Early Insulin Use in Type 2 Diabetes: What are the cons?
por: Chiasson, Jean-Louis
Publicado: (2009)

Plasma Glucose Concentration and Prediction of Future Risk of Type 2 Diabetes
por: Abdul-Ghani, Muhammad A., et al.
Publicado: (2009)

Antioxidant Anti-Inflammatory Treatment in Type 2 Diabetes
por: Ceriello, Antonio, et al.
Publicado: (2009)

Telemedical Artificial Pancreas: PARIS (Páncreas Artificial Telemédico Inteligente) research project
por: de Leiva, Alberto, et al.
Publicado: (2009)

Self-Monitoring of Blood Glucose as Part of the Integral Care of Type 2 Diabetes
por: Boutati, Eleni I., et al.
Publicado: (2009)

GLP-1 Receptor Agonists in Type 2 Diabetes and Beyond – New Insights 2015
por: Gallwitz, Baptist
Publicado: (2015)

The Cardiovascular Benefits Associated with the Use of Sodium-Glucose Cotransporter 2 Inhibitors – Real-World Data
por: Gallwitz, Baptist
Publicado: (2018)

Cardiovascular Outcomes with Empagliflozin – News for Type 2 Diabetes Therapy
por: Gallwitz, Baptist
Publicado: (2016)

Is the Diminished Incretin Effect in Type 2 Diabetes Just an Epi-Phenomenon of Impaired β-Cell Function?
por: Meier, Juris J., et al.
Publicado: (2010)

Implications of Postprandial Glucose and Weight Control in People With Type 2 Diabetes: Understanding and implementing the International Diabetes Federation guidelines
por: Gallwitz, Baptist
Publicado: (2009)

The incretin/glucagon system as a target for pharmacotherapy of obesity
por: Del Prato, Stefano, et al.
Publicado: (2021)

Glucokinase Activators for Diabetes Therapy: May 2010 status report
por: Matschinsky, Franz M., et al.
Publicado: (2011)

Type 2 Diabetes Can Be Prevented With Early Pharmacological Intervention
por: DeFronzo, Ralph A., et al.
Publicado: (2011)

Long-Term Benefits From Lifestyle Interventions for Type 2 Diabetes Prevention: Time to expand the efforts
por: Tuomilehto, Jaakko, et al.
Publicado: (2011)

Safety of PPAR Agonists
por: Home, Philip
Publicado: (2011)

Pivotal Role of Timely Basal Insulin Replacement After Metformin Failure in Sustaining Long-Term Blood Glucose Control at a Target in Type 2 Diabetes
por: Bolli, Geremia B., et al.
Publicado: (2011)

Insulin: Potential Negative Consequences of Early Routine Use in Patients With Type 2 Diabetes
por: Lebovitz, Harold E.
Publicado: (2011)

Multidrug Treatment of Type 2 Diabetes: A challenge for compliance
por: Miccoli, Roberto, et al.
Publicado: (2011)

Role of Bile Acid Sequestrants in the Treatment of Type 2 Diabetes
por: Handelsman, Yehuda
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_mdu9ban0l02o1sf60u8l8cs4et